JP2013537182A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537182A5
JP2013537182A5 JP2013527670A JP2013527670A JP2013537182A5 JP 2013537182 A5 JP2013537182 A5 JP 2013537182A5 JP 2013527670 A JP2013527670 A JP 2013527670A JP 2013527670 A JP2013527670 A JP 2013527670A JP 2013537182 A5 JP2013537182 A5 JP 2013537182A5
Authority
JP
Japan
Prior art keywords
composition according
sodium
particles
polymer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013527670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/000785 external-priority patent/WO2012035283A1/en
Publication of JP2013537182A publication Critical patent/JP2013537182A/ja
Publication of JP2013537182A5 publication Critical patent/JP2013537182A5/ja
Ceased legal-status Critical Current

Links

JP2013527670A 2010-09-13 2011-05-23 医薬組成物 Ceased JP2013537182A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2522/MUM/2010 2010-09-13
IN2522MU2010 2010-09-13
IN2539/MUM/2010 2010-09-14
IN2539MU2010 2010-09-14
PCT/GB2011/000785 WO2012035283A1 (en) 2010-09-13 2011-05-23 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2013537182A JP2013537182A (ja) 2013-09-30
JP2013537182A5 true JP2013537182A5 (enExample) 2014-07-10

Family

ID=44169144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527670A Ceased JP2013537182A (ja) 2010-09-13 2011-05-23 医薬組成物

Country Status (13)

Country Link
US (1) US20130315988A1 (enExample)
EP (1) EP2616044A1 (enExample)
JP (1) JP2013537182A (enExample)
KR (1) KR20140029356A (enExample)
CN (1) CN103221032A (enExample)
AU (1) AU2011303715A1 (enExample)
BR (1) BR112013005772A2 (enExample)
CA (1) CA2810598A1 (enExample)
MX (1) MX2013002802A (enExample)
NZ (1) NZ607935A (enExample)
RU (1) RU2013113752A (enExample)
WO (1) WO2012035283A1 (enExample)
ZA (1) ZA201301920B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
WO2015140569A1 (en) * 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016014437A1 (en) * 2014-07-21 2016-01-28 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
ES2979135T3 (es) 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina
WO2020219406A1 (en) * 2019-04-22 2020-10-29 Mylan Specialty L.P. Meloxicam co-crystal compositions
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CN100490790C (zh) * 2007-04-28 2009-05-27 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
JP2009137922A (ja) * 2007-11-16 2009-06-25 Kaneka Corp リファマイシン誘導体を傷害組織にデリバリーする製剤
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes

Similar Documents

Publication Publication Date Title
JP2013525337A5 (enExample)
RU2013113752A (ru) Фармацевтическая композиция
JP2013538845A5 (enExample)
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP2012136541A5 (enExample)
JP2013519645A5 (enExample)
JP2013542945A5 (enExample)
JP2013530158A5 (enExample)
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
MX364938B (es) Formulaciones de apixaban.
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
JP2011525477A5 (enExample)
JP2010527365A5 (enExample)
EP3656740A3 (en) Titanium oxide fine particles and method for producing same
JP2016518398A (ja) 低用量医薬組成物
MX2023002994A (es) Formas de dosificacion oral y de liberacion controlada gastrorresistentes.
WO2010146409A3 (en) Nanoparticulate candesartan cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them
MX337827B (es) Novedosos derivados polisacaridos y formas de administracion.
CN104721156A (zh) 一种含利伐沙班的片剂
JP2019511465A5 (enExample)
ME01439B (me) Kompozicije flupentiksola
MY164765A (en) Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil